石四药集团(02005.HK)：氨吡啶已获国家药监局批准登记成为在上市制剂使用的原料药

Core Viewpoint - The announcement highlights that Stone Four Pharmaceutical Group has received approval from the National Medical Products Administration of China for its Amaprine to be registered as an active pharmaceutical ingredient for use in marketed formulations, making it the first company in the country to achieve this [1] Company Summary - Stone Four Pharmaceutical Group's Amaprine is a potassium channel blocker primarily used to improve walking speed in adults with certain types of multiple sclerosis [1]